OBIO Similar Chart Price Prediction
The price of OBIO is predicted to go up 3.92%, based on the high correlation periods with MATH. The similarity of these two price pattern on the periods is 97.32%.
OBIO
MATH
Up: 3.92%Similarity: 97.32%
OBIO Revenue Forecast
OBIO EPS Forecast
OBIO FAQs
What is OBIO revenue forecast for next quarter？
OBIO Analyst's Forecast
Marie Thibault
BTIG
Strong Buy
2025-03-20
Price Target
$12
Upside
+175.86%
BTIG analyst Marie Thibault initiated coverage of Orchestra BioMed with a Buy rating and $12 price target. Orchestra is a medical technology company with a "unique business model maximizing its expertise in research and development while partnering with large companies to bring new devices to market, the analyst tells investors in a research note. The firm says the company's first two products are focused on the large, underserved markets of hypertension and coronary artery disease. While Orchestra is still proving out its business model, there is "plenty to like with the approach," contends BTIG.
Matt Miksic
Barclays
Buy
2025-01-02
Price Target
$16
Upside
+197.4%
